Northwest Biotherapeutics (NWBO.OB) Reports Stimulating Follow-Up Data to Clinical Trials for its Brain Cancer Treatment
Northwest Biotherapeutics, Inc. (www.nwbio.com) today (Tuesday, August 3) reported some excellent long-term follow-up data related to previous Phase I and Phase I/II clinical trials for its DCVax®-Brain personalized immune therapy, which was devised for the most aggressive and lethal brain cancer ever seen, the newly diagnosed Glioblastoma multiforme (GBM). The Company is a development-stage biotech pioneer specializing in immunotherapy that utilizes proprietary techniques for activating the immunological system of the patient. Such technology is a powerful step forward for oncology applications and cancer patients alike. The data coming in looks really good: • No patient deaths in the nine months…